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Kia ora Dr. Cobb 
 
On 31 July 2019 you requested from me a formal submission to a Decision-Making Committee (DMC) 
reconsidering the 2018 determination (EPA 2018a) to not class cells or organisms treated externally with 
double-stranded (ds)RNA molecules as new or genetically modified organisms. I welcome EPA’s decision to 
reconsider its determination on application APP203395. In response to your request I provide the following 
four documents as my complete submission to the DMC: 
1. This letter. 
2. A submission on scientific and other matters.  
3. My comprehensive and peer-reviewed paper examining the scientific basis of the New Zealand 
Environmental Protection Authority HSNO Decision-Making Committee’s May 2018 
determination, which I sent to EPA on 4 June 2019 (Heinemann 2019).1 This paper provided the 
EPA with new information that demonstrated that the DMC of the day was mistaken in relying 
upon the stated biological barriers to dsRNA causing heritable effects in eukaryotic organisms and 
it overlooked known heritable effects, some in pre-commercial stages of exploitation. Moreover, 
it failed to account for effects on exposed inseparable prokaryotic organisms. 
If a gene technology meets the test of heritability it is sufficient to conclude that external 
treatments of organisms with dsRNA creates genetically modified organisms. The barriers that the 
DMC relied upon to disqualify external treatments from causing heritable effects are stated in 
paragraph 4.6 of its decision. They are that the dsRNA remains “solely as RNA molecules in the cell 
cytoplasm outside the nucleus, and therefore they do not integrate into the DNA of the eukaryote 
genome”, is “not reverse-transcribed into DNA”, and is “therefore not inheritable by the organism.” 
The DMC was wrong to rely on these barriers.  
• The membrane surrounding the nucleus is not maintained in all eukaryotic organisms. In animals, it 
is degraded once per cell cycle leading to mixing of nuclear and cytoplasmic content. Moreover, in 
many eukaryotes dsRNA is recruited to the nucleus in association with nucleus-localising proteins. 
• There was no evidence to assert that dsRNA cannot be reverse transcribed, and no literature 
foundation that I could find provided certainty for this assertion for all eukaryotic species. 
• In fungi at least there are replicating RNA molecules in the cytoplasm that express their genes and 
                                               
1 https://www.sciencedirect.com/science/article/pii/S0160412019306038 
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recombine with new RNA molecules taken into the cytoplasm. Moreover, in some eukaryotes 
dsRNA modifies chromosomes by causing DNA rearrangements and can increase the transition 
mutation rate of G:C pairs to A:T pairs. Finally, the EPA and the DMC did not account for the 
heritable effects externally applied dsRNA has by competing with endogenously produced dsRNA. 
Potential adverse effects to human health or the environment that might result from treatments using 
dsRNA would not be considered if the May 2018 determination stands. Implications of the determination 
include but are not limited to— 
• heritable changes in both targeted and non-target but exposed organisms. Neither the EPA nor the 
DMC appeared to consider the potentially harmful effects to human health, companion animals, 
livestock and beneficial plants, insects, protists, fungi and bacteria from exposures to unregulated 
open-air dispersals of dsRNA, which are not fully predictable from sequence information alone 
(Heinemann et al. 2013; NASEM 2016). 
• the release of partial or whole viruses with RNA genomes. Penetration of RNA into plant, animal 
and fungal cells can be accomplished using simple and otherwise non-hazardous chemicals as 
delivery vehicles. Because these same formulations also cause penetration of cells by DNA, 
unintended release of viruses with DNA genomes is also possible. These viruses may cause disease 
in organism exposed on purpose or by accident. 
• use of this method anywhere, anytime and on any kind of organism (not controlled under the 
Biosecurity Act or already genetically modified), including potential disease-causing 
microorganisms. 
• effects on still to be described species. Neither the EPA nor the DMC were hesitant to extrapolate 
from the literature on RNA interference which is informed by a relatively small number of research 
organisms to all eukaryotes, even the thousands that are yet to even be described in New Zealand. 
As the US National Academies concluded: “More research is required to address the sustainability 
of, and off-target effects arising from, RNAi approaches” (NASEM 2016). The paper most frequently 
cited by EPA staff in their report says in bold type at the very beginning: “Recent advances have 
revealed unexpected diversity in their biogenesis pathways and the regulatory mechanisms that 
they access.” Later the same review concludes: “We are rethinking our views as to what constitutes 
an siRNA or miRNA. The rules about biogenesis and action are much more fluid than we thought” 
(Carthew and Sontheimer 2009). 
Without knowledge of the genomes of undescribed species there would be no ability to design 
dsRNAs that had no targets in these organisms. Risk mitigation would require controls to limit 
exposures. Such controls could only be achieved if the use of external treatments was regulated. 
4. A comprehensive and peer-reviewed paper examining the kinds of chemical and physical vectors, 
mentioned briefly above, that are in development for use as delivery vehicles for external dsRNA 
treatments (Heinemann and Walker). It further evaluates risks that should be considered on a 
case-by-case basis by a precautionary regulator. 
• It is obvious that external application of dsRNA to cells or organisms can have adverse effects 
because most of the first such products are intended to have adverse effects (usually lethal, but 
sometimes intergenerational) because they are pesticides. 
• Even lawful uses may cause harm through off-target effects, and these off-target effects cannot be 
predicted with accuracy. Exposures are designed to be at combination of concentrations, pathways 
of exposure and/or using active molecules that are not found in nature. 
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• The use of nucleic acids that do not occur in nature as well as stabilizing forms that otherwise 
would not be suitable for external treatments, including single-stranded DNA, single-stranded RNA 
(e.g. guide RNAs) and chimeric mixtures of DNA and RNA are described in patents. Over 100 known 
chemical modifications can be added to in vitro synthesized RNA molecules. 
• Exposures to externally applied dsRNAs besides by ingestion have received far less attention, 
especially in humans and other large animals. Importantly, even less is known about the effects of 
co-formulants on the stability and effectiveness of the dsRNA. This cannot be known until tested 
and only will be tested if they are subject to regulatory oversight. Outside of pharmaceuticals, we 
did not find much discussion on purposeful inhalation exposure but we did find many references to 
application technologies that create the potential for such exposure, for example by aerosolization 
through spray applicators. At present, there is insufficient knowledge of these exposure pathways to 
justify deregulation of external dsRNA treatments. 
• Nothing is known of the potential to tamper with products that cause uptake of dsRNA. Without 
post-market risk mitigation strategies that could come from a pre-market risk assessment, we may 
not know until after harm has been caused. 
 
The Environmental Protection Authority will always be 
challenged in the fast-paced arena of biotechnology. Fortunately, 
the HSNO Act provides a solid foundation for guidance and 
direction on the kinds of biotechnologies that cause concern if or 
when they are used in the environment. In essence, if either an in 
vitro technique modifies a gene or genetic material of an 
organism, or an organism is descended from one with modified 
genes or genetic material, EPA has been tasked with evaluating it 
for safe use or release. 
I believe that the use of dsRNA for external treatments of cells or 
organisms could provide benefits. However, it is a gene 
technology and requires oversight. 
I wish to draw attention to use of confusing, ambiguous, 
sometimes conflicting, descriptions of terms, purposes and scope 
in APP203395. One clear example is the important distinction 
between how you described the determination in your 31 July 
2019 letter to me, which is consistent with the May 2018 
decision paragraph 1.1, but which is not consistent with decision 
paragraph 6.1. The decision as stated in paragraph 6.1 is not 
limited by the intention2 of the treatment (EPA 2018a). 
Moreover, neither paragraph 1.1 nor 6.1 provides guidance on 
how the treatment would be restricted to causing only the 
intended response, range of sizes and other characteristics of 
molecules that might be described as siRNA or dsRNA, the 
temporal and biochemical range of potential responses, and 
what is meant by the undefined term “siRNA response”.3  
                                               
2 Intention of treatment is limited in paragraph 1.1 of DMC decision: “treated…to induce a small interfering RNA 
(siRNA) response.” 
3 I could find no mention of the term “siRNA response” searching within the key references in the EPA staff report. 
Biodiversity of potentially exposed 
environments is both high and largely 
undescribed (USDA ; Womack et al. 2010) 
making it both difficult to limit exposures 
to intended species and predict the effects 
of all exposures. Airborne microorganisms 
including eukaryotes can number in the 
hundreds of thousands per m3 and “can be 
as diverse as those in terrestrial 
environments, including soils” (Womack et 
al. 2010). 
Metagenomics surveys indicate from 
10,000-830,000 species per gram of soil 
(Dance 2008). According to the United 
Nations Food and Agriculture 
Organization: “Over 1000 species of 
invertebrates may be found in a single m2 
of forest soils. Many of the world’s 
terrestrial insect species are soil dwellers 
for at least some stage of their life-cycle. A 
single gram of soil may contain millions of 
individuals and several thousand species of 
bacteria. A typical, healthy soil might 
contain several species of vertebrate 
animals, several species of earthworms, 
20-30 species of mites, 50-100 species of 
insects, tens of species of nematodes, 
hundreds of species of fungi and perhaps 
thousands of species of bacteria and 
actinomycetes. Soil contains the organism 
with the largest area. A single colony of 
the honey fungus, Armillaria ostoyae, 
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4 Homologous means related by descent. 
Table 1. Purpose of the application 
Source Description‡ Notes 
Application “To obtain a 
determination of whether an 
organism is a new organism” 
APP203395 (Trought, 2018). 
Eukaryotic cells that have 
been transiently transfected 
with synthetic molecules of 
double stranded RNA to 
inhibit (temporarily) the 
activity of the 
complementary RNA. 
Application for eukaryotic 
cells (which may be tissue 
culture) becomes a 
determination for all 
eukaryotic organisms. 
Application for use of 
synthetic/artificial dsRNA 
molecules contrasts with 
determination for all dsRNA 
molecules of undisclosed 
source, size or other 
characteristics. 
Application originally limited 
to an activity on the mRNA 
target that is temporary 
changed to a decision 
allowing any form of 
expression suppression and 
then to any dsRNA treatment 
outcome. 
EPA Staff Report 
“Determining whether 
eukaryotic cell lines treated 
with double-stranded RNA 
are genetically modified 
organisms” (EPA, 2018b). 
[the applicant] seeks a 
determination…on whether 
eukaryotic cells treated with 
artificially synthesised dsRNA 
to transiently suppress the 
expression of user-selected 
genes are new organisms for 
the purpose of the Act.  
EPA Decision “Purpose of the 
Application” page 1 (EPA, 
2018a). 
“eukaryotic cell lines that 
have been treated with 
externally applied double-
stranded RNA molecules for 
the purpose of inducing a 
transient small interfering 
RNA (siRNA) response are 
new organisms.” 
EPA Decision section 2 (EPA, 
2018a). 
“eukaryotes treated with 
double-stranded RNA 
molecules were considered 
genetically modified 
organisms.” 
‡Highlighted terms are inferred as homologous4 in the different passages.  
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The former DMC described the application in various, and significantly different, ways (Table 1) from the 
applicant (Trought 2018) or EPA staff (EPA 2018b). The applicant sought permission to use “synthetic” 
dsRNA, restricted as well to those that would cause a temporary effect on and only on the “activity of the 
complementary RNA” and in eukaryotic cells (Trought 2018). The purpose of the application was restated 
more or less similarly by EPA staff but not by the DMC (Table 1). The DMC introduced the phrase “eukaryotic 
cell lines” to the stated purpose, which could imply a narrowing of the scope to tissue culture or other 
“certain cells” as mentioned in a press release (Figure 1).5 Simultaneously the DMC introduced the 
terminology “siRNA response”. Whereas the applicant also conflates the active molecule siRNA with a 
process (“the siRNA process”), it never uses the term siRNA response, instead referring to RNA interference. 
Did the DMC mean RNA interference by the phrase “siRNA response”, or something less comprehensive 
than RNA interference? If so, why and how would any treatment be able to avoid RNA interference? What 
about exposures to siRNA molecules that cause effects other than RNA interference, but would certainly 
then be siRNA responses and not necessarily RNA interference, such as occurs in environmentally 
inseparable prokaryotes6 (Heinemann 2019; Shabalina and Koonin 2008)? An EPA press release implied that 
many kinds of eukaryotes that are not plants or animals also had not been considered (Figure 1). Only 
                                               
5 I consider the press release had the potential to mislead the public through its suggestion that the decision applies 
only to plant and animal exposures, only certain cells, and would be limited to effects on protein production. None of 
these kinds of restrictions are inherent in the decision. 
6 This quote is from the Shabalina and Koonin (2008) paper frequently cited by EPA staff in their report. “RNAi-like 
mechanisms do exist in prokaryotes and seem to show functional analogies both to the miRNA and the siRNA 
pathways of eukaryotes, even though the proteins involved in these processes are nonhomologous.” 
Figure 1. EPA press release. 
 
https://www.epa.govt.nz/news-and-alerts/latest-news/leading-edge-plant-and-animal-research-not-
gmo/ Access date 3 September 2019. 
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plants and animals were mentioned, and only “certain cells” of them. The announcement gave no indication 
of how treatments would be so finely controlled that only selected cells of only plants and animals would be 
exposed. 
The scope changes later in the DMC decision and conclusion text. At this stage there is no longer a specific 
reference to cells. Now it becomes clear that the determination is not restricted to cell lines but applies to 
organisms and cells (and some eukaryotes are single-celled organisms). The rephrasing releases the 
treatment from effects only on mRNA molecules, making possible the many other kinds of effects dsRNA, 
including siRNA, can have on DNA or other genetic material (reviewed in Heinemann 2019; Heinemann et 
al. 2013). The final text also removed any need to confine the treatments to those that had only temporary 
effects (which in any case were never defined). While section 26 of the HSNO Act gives considerable power 
to the DMC, it surely cannot use any application as a pretext to make any kind of determination on 
anything. Therefore, how are these significant variations introduced after the application and staff report 
justified by the DMC? 
The DMC removed the terms “synthetic” (used by the applicant) 
and “artificially synthesised” (used by EPA staff) for delimiting 
the kind of dsRNA molecules used in treatments. Those terms 
emphasise that treatments involve in vitro techniques. As I 
explain in my submission document on further scientific and 
other matters, use of in vitro techniques is an unavoidable test 
of whether an organism is a new organism. Accepting the use of 
these techniques as affecting genes or other genetic material, 
as they do, would have been sufficient evidence to determine 
that eukaryotic cells or organisms treated externally with dsRNA 
were new and genetically modified organisms.  
However, even if the determination could be restricted 
somehow to avoid in vitro techniques in the construction of the 
dsRNA molecules -  which I do not believe is possible to do - the 
determination would not change. This is because the methods 
used to penetrate cells or organisms with dsRNA molecules is 
also a kind of in vitro technique, just as it is when DNA 
molecules are used to create genetically modified organisms. 
Finally, I would like to say that whereas dsRNA-based gene 
technologies may prove to be beneficial, only a proper risk 
assessment can determine when their use might be 
inappropriate. For example, the effects of using dsRNA on 
protists has different potential harm pathways (not extreme or 
unusual or unrepresentative, just different) than on plants. In 
some environments, dsRNA is far more stable than previously 
assumed because soil absorption has been mistaken for 
degradation, and it is also bio-available to microorganisms 
(Parker et al. 2019). The EPA decision as it stands rules out 
making case-by-case assessments because it does not require 
any future risk assessment to be made before use.  
Some of the most interesting and 
unexpected effects of dsRNA on eukaryotes 
are observed in the protists. These 
organisms are ubiquitous in outside 
environments where dsRNA products may 
be used and yet many of these organisms 
are still to be described. “Toward the end 
of the last millennium, there was an 
estimated 4,300 described free-living 
ciliate species. In the new millennium, 
species of free-living ciliates are being 
described at an average rate of ~50 per 
year” (Warren et al. 2017). 
They are far too numerous to be 
considered either as extreme or special 
cases. Populations range from 1000s of 
protozoans per gram of agricultural soil, to 
10s of thousands in prairie soils up to 100s 
of thousands in forest soils (Fortuna 2012). 
They provide critically important 
ecosystem services. “Heterotrophic 
microeukaryotes such as ciliates are 
thought to be of considerable importance 
in aquatic ecosystems, as they are major 
predators of bacteria and constitute a 
nutritional resource for other protozoa, 
invertebrates, and probably fish larvae. In 
addition, protozoan bacterivory 
contributes to enhanced decomposition of 
leaf detritus—a vital nutrient resource in 
streams—by increasing turnover of 
bacterial populations through predation” 
(Dopheide et al. 2009). The effects of 
dsRNA on the DNA components of 
protozoan genomes demonstrates that 
treatments with dsRNA are within scope of 
the HSNO Act and effects should be 
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Recommendations 
In view of the information I have presented in the four documents that compose this submission, I 
recommend to the DMC that it— 
1. retract the 1 May 2018 decision on application APP203395. 
2. issue a new decision that in accordance with section 26 of the Act, and having regard to the 
relevant information, the EPA has determined that cells or organisms that have been treated with 
externally applied double-stranded RNA are new organisms for the purpose of the Act. 
Once it has been decided that external treatments of eukaryotes create genetically modified organisms, it 
may be appropriate to simplify risk assessment procedures in some cases. Tissue culture experiments in 
contained laboratories may have negligible potential to cause harm. Risk could similarly likely be managed 
for treatments occurring in contained glasshouses where plants are the subject of experimentation and so 
long as other potentially exposed organisms cannot escape. As forecast by the EPA, however, this 
technology is intended to be used out-of-doors at least by some and may be used by anyone using easily 
accessed chemicals or abrasives (see my submission document four). The outdoor applications will use 
chemical or physical vehicles that alter the efficiency of uptake of dsRNA to levels that do not occur in 
nature, and by exposure pathways that have been little studied. Therefore, regulation of external 
treatments of organisms with dsRNA is the option consistent with the purpose and principles of the new 
organism provisions of the HSNO Act. 
 




Dr Jack A Heinemann 
Professor of Molecular Biology and Genetics7 
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